Elixinol Global (ASX:EXL)

  • Symbol:ASX:EXL
  • Ticker 2:OTCMKTS:ELLXF
  • Sector:Healthcare
  • Industry:Pharmaceutical
  • CEO:Stratos Karousos
  • Founded:2014
Categories:

Elixinol Global (ASX:EXL) Stock Price

Disclaimer: Past performance is not an indicator of future performance.

Elixinol Global (ASX:EXL) Company Overview

Elixinol Global, which operates in the industrial hemp, dietary supplements and emerging medicinal cannabis sector, comprises three separate companies. Elixinol US is the main business unit. The company manufactures and distributes hemp-based dietary and skincare products to the US market and exports to another 40 countries globally (including the first-ever CBD-based product to Japan in mid-2018).

With revenues of $12.5 million in the first 6 months of 2018 (up 119%), and a growing relationship with Kelsey AG in Colorado, this business should see significant growth in 2019 and is in our opinion, the only part of the company offering real value to investors right now. The other two companies both operate out of Australia. Hemp Foods Australia sells hemp foods and seeds via both a retail network and wholesale channels.

And finally, there is Elixinol Australia, a late-stage medicinal marijuana applicant, that will be looking to produce premium medicinal marijuana for the emerging Australian medicinal market. A great performer in 2018, we continue to believe that Elixinol has huge upside, and with the passing of the Farm Bill, and a booming CBD-wellness industry in play, are very well placed to grow their US market share.

Investor Presentation

The latest update from the company

Click Here
Stay updated about
this company

Signup to get updates.